Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond ...
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development ...
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Justera Health Ltd. (CSE:VTAL)(OTC PINK:SCRSF) ("Justera"or the"Company") is pleased to announce the changes to the leadership to the Company.The Company ...
MIDLAND, MI and SAINT JOHNS, MI / ACCESSWIRE / November 14, 2024 / Michigan Psychological Care is excited to announce the ...
Eisai Europe Ltd. and Biogen Inc. announced today that a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
BOULDER, CO / ACCESSWIRE / November 15, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant ...
A new report from the Office of Health Economics (OHE) reveals how NICE may be systematically undervaluing medicines for severe medical conditions, including terminal cancer, compared to how the ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Sanofi today announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). Rippon will continue her role as Country Lead for Sanofi UK & Ireland alongside this ...
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback